On October 7, 2011, the FDA approved an oral combination of sitagliptin/simvastatin marketed in the US as Juvisync.
On October 7, 2011, the FDA approved a pharmaceutical combination containing sitagliptin and simvastatin, which was marketed as Juvisync in the US.